Glucagon-like peptide 1 (GLP-1) based therapies, including GLP-1 agonists, are currently in use for treatment of diabetes and obesity. However, several complications may occur with their use. This narrative review provides a focused evaluation of GLP-1 agonist therapy and associated complications ...
Unlocking the broad health benefits and risks of GLP-1 receptor agonist drugs Nature Medicine Research Briefing 23 Jan 2025 Sections Figures References Abstract Data availability Code availability Change history References Acknowledgements Author information Ethics declarations Peer review Additional information...
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist 97% similar to native GLP-17 which is secreted by intestinal L-cells at the level of the distal jejunum, ileum and colon in response to the ingestion of carbohydrates, lipids and mixed food. It reduces blood sugar levels, ...
1. Introduction 2. Methods 3. Physiology of glucagon-like peptide-1 (GLP-1) 4. Glucagon-like Peptide-1 agonists: pharmacology and current status 5. Multi-agonist approach 6. Conclusion Funding Conflict of interest Acknowledgement ReferencesShow full outline Cited by (210) Figures (3) Tables ...
H. et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58, 975–983 (2009). Article CAS PubMed PubMed Central Google Scholar Nikolaidis, L. A. et al. Effects of glucagon-like peptide-1 in ...
The impact of glucagon-like peptide-1 receptor agonist on the gastric residue in upper endoscopy. Diabetes Res Clin Pract. 2024;217:111900. doi:10.1016/j.diabres.2024.111900. (Open in a new window)PubMed (Open in a new window)Web of Science ®(Open in a new window)Google Scholar...
ArticleCASPubMedGoogle Scholar Werner, U., Haschke, G., Herling, A. W. & Kramer, W. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.Regul. Pept.164, 58–64 (2010). ArticleCASPubMedGoogle Scholar ...
Suspected clinical impacts of GLP-1RAs, SGLT2is, and finerenone oncardiovascular and kidney outcomes. CV, cardiovascular; GLP-1RA, glucagon-like peptide-1 receptor agonist; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; MI, myocardial inf...
The GLP-1 agonist drugs help with weight loss by helping people feel fuller on less food, decrease appetite andreduce cravingsfor low-qualityjunk food. They do this by increasing levels of GLP-1, a hormone that promotes feelings of fullness. The good news is we can increase t...
一、GLP1的发现 上世纪中后期，人们发现肠道提取物具有降低血糖的作用。此外，将葡萄糖注射到肠道比注射...